Gabelli & Co Investment Advisers’s SpringWorks Therapeutics SWTX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-324,350	Closed	-$15.2M	–	323
2025 Q2	$15.2M	Buy	324,350 +282,100	+668%	+$12.6M	2.34%	13
2025 Q1	$1.86M	Buy	+42,250	New	+$1.94M	0.28%	70

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Gabelli & Co Investment Advisers's SWTX Position: Q3 2025 in Review

Gabelli & Co Investment Advisers sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 324,350 shares — an estimated $15.2M sold.

Gabelli & Co Investment Advisers first reported a position in SWTX in Q1 2025 and held it in 2 quarters. The position peaked at $15.2M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Gabelli & Co Investment Advisers reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 324,350 SpringWorks Therapeutics shares in Q3 2025, an estimated $15.2M.
Gabelli & Co Investment Advisers first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 2 quarters.
Gabelli & Co Investment Advisers's SpringWorks Therapeutics position peaked at $15.2M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2025, filed 12 Nov 2025.